Baudax Bio Inc. (BXRX)
0.02
-0.00 (-1.48%)
At close: Feb 29, 2024, 8:53 PM
-1.48% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | 326K |
| Net Income (ttm) | -7.15M |
| EPS (ttm) | -94.13 |
| PE Ratio (ttm) | -0.00023159460320832891 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 310,872 |
| Avg. Volume (20D) | 424,847 |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.02 - 0.02 |
| 52-Week Range | 0.01 - 3.47 |
| Beta | 1.58 |
About BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2019
Employees 9
Stock Exchange NASDAQ
Ticker Symbol BXRX
Website https://www.baudaxbio.com